Key Highlights

• Mixed Analyst Landscape: Goldman Sachs nudged its price target to 310 Danish kroner while Morningstar downgraded the stock to Hold.

• Medicare Bridge Program Launch: The program temporarily covers Wegovy at a $50 monthly copay for eligible seniors, a pool estimated at 15-20 million.

• Trading Above Goldman's Target: The stock trades above Goldman's reiterated Neutral price target in Copenhagen trading.

Novo Nordisk (NYSE: NVO) shares are edging modestly lower, consolidating near recent highs as investors weigh a mixed analyst landscape and a landmark Medicare policy shift that could significantly expand the company's addressable patient population.

Goldman Sachs recently nudged its price target to 310 Danish kroner while reiterating a Neutral rating, with the stock trading above that target in Copenhagen, suggesting the market may already be pricing in more optimism than Goldman's formal assessment reflects.

Morningstar downgraded the stock to Hold, adding to the mixed sentiment picture as the analyst community appears genuinely divided on the company's near-term valuation relative to its growth prospects in the competitive GLP-1 drug market.

A major catalyst looms in the form of Medicare's "Bridge" program, which launches this week, temporarily covering Wegovy at a $50 monthly copay for eligible seniors — a pool Novo Nordisk estimates at 15 to 20 million older adults.

This Medicare policy shift could potentially accelerate GLP-1 demand significantly, representing a structural tailwind that investors are weighing against the more cautious near-term analyst sentiment reflected in recent rating actions.

()